Recombinant Oreochromis niloticus Somatostatin-2 (sst2)

What is Oreochromis niloticus Somatostatin-2 and how is it identified in the tilapia genome?

Somatostatin-2 (sst2) is one of three somatostatin peptides expressed in tilapia (Oreochromis niloticus). According to RNA sequencing data of mature tilapia brain tissue, it is referred to as SST3 in genomic annotations. The gene is officially designated as LOC100694069 encoding protein XP_003448989.2 . Somatostatin peptides in vertebrates group into six distinct phylogenetic clades, with SST3 arising from tandem duplications of SST1 . Genomic and synteny analyses show that sst2/SST3 in tilapia is related to sstr5a found in the holostean spotted gar (Lepisosteus oculatus) .

What are the primary physiological functions of somatostatin-2 in tilapia?

Somatostatin-2 (SST3) in tilapia primarily functions as a neuromodulator involved in regulating both growth and reproductive hormones. Research indicates that the somatostatin system plays a role in:

• Inhibiting growth hormone secretion from the pituitary

• Regulating gonadotropins, specifically follicle-stimulating hormone (FSH) and luteinizing hormone (LH)

• Modulating prolactin release, which affects osmoregulation in tilapia

The somatostatin system achieves these functions by activating G protein-coupled receptors, triggering adenyl cyclase inhibition, reducing intracellular cAMP, protein kinase A activity, and Ca²⁺ channel function, while activating K⁺ channels .

How does somatostatin-2 differ from other somatostatin variants in tilapia?

Tilapia express three distinct somatostatin peptides with varying expression levels:

• SST6 (Somatostatin-1B, protein ID: XP_003444846.1)

• SST3 (Somatostatin-2, protein ID: XP_003448989.2)

• SST1 (Somatostatin-1, gene ID: LOC100693797) expressed at low levels

These variants differ in their evolutionary origin, sequence, structure, and likely in their receptor binding profiles and physiological functions. Phylogenetic analysis revealed that somatostatin genes in vertebrates form six distinct clades, with different evolutionary origins through genome duplications and tandem duplications .

Which somatostatin receptors interact with somatostatin-2 in tilapia?

Four different isoforms of somatostatin receptors (SSTRs) were identified in the tilapia genome. RNA sequencing of separated pituitary cell populations showed that:

• SSTR3a is enriched in luteinizing hormone (LH) cells

• SSTR3b is significantly enriched in follicle-stimulating hormone (FSH) cells

While the research doesn't explicitly state which receptors preferentially bind SST3 (somatostatin-2), the receptor binding studies showed that octreotide (an SSTR agonist) exhibited a binding profile similar to that observed in human receptors, suggesting some conservation of binding preferences .

What molecular mechanisms underlie somatostatin-2 signaling in tilapia reproduction?

Somatostatin-2 (SST3) appears to regulate reproductive hormones through complex signaling pathways involving SSTRs expressed in gonadotrophs. Research indicates:

• SSTRs activate G protein-coupled receptors, inhibiting adenyl cyclase and reducing intracellular cAMP

• Octreotide (SSTR agonist) decreased FSH levels after 2 hours of injection, while LH levels remained unaffected

• Cyclosomatostatin (SSTR antagonist) increased both LH and FSH plasma levels 2 hours post-injection

• Ca²⁺ signaling appears critical in somatostatin's inhibitory effects, as calcium exclusion blocked hormone release even in the presence of calcium ionophores

• Both dibutyryl cAMP (dbcAMP) and the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine were effective in preventing somatostatin-induced inhibition of hormone release

These findings suggest that somatostatin-2 likely regulates reproduction by modulating both calcium and cAMP-mediated signaling pathways in pituitary gonadotrophs.

How do the structural characteristics of recombinant somatostatin-2 influence its receptor binding and specificity?

Three-dimensional in silico models for tilapia SSTRs (tiSSTR2a, tiSSTR3a, tiSSTR5b, and tiSSTR3b) and SSTs (tiSST6 and tiSST3) were prepared using the I-TASSER server with human SSTR2-huSST-14 (PDB:7T10) as a template . The binding site analysis of tiSSTRs from tilapia pituitary cells revealed the presence of canonical binding sites characteristic of peptide-binding class A G-protein-coupled receptors .

The structural models were selected based on:

• Structural stability

• C-score (confidence score)

• Structural similarity with known human SSTR2 structure

While not explicitly detailed in the search results, the conserved binding profile of octreotide (similar to human receptors) suggests that key binding determinants may be conserved between tilapia and human somatostatin receptors, despite evolutionary divergence .

What are the challenges in expressing and purifying functional recombinant somatostatin-2 from tilapia?

While the search results don't directly address the challenges of expressing and purifying recombinant somatostatin-2 from tilapia, several inference-based challenges can be anticipated:

• Maintaining proper disulfide bond formation, which is critical for somatostatin's biological activity

• Achieving correct post-translational modifications

• Ensuring proper folding of the recombinant peptide

• Developing purification strategies that yield high purity without compromising bioactivity

• Establishing appropriate assays to confirm the biological activity of the recombinant protein

The successful production of recombinant somatostatin-2 would likely require optimization of expression systems (bacterial, yeast, or mammalian), purification protocols, and functional validation using techniques such as receptor binding assays and in vivo testing as described in the research .

How do environmental factors affect somatostatin-2 expression and function in tilapia?

While the search results don't directly address environmental influences on somatostatin-2 expression, we can infer potential relationships based on tilapia physiology:

Further research specifically targeting the relationship between environmental factors and somatostatin-2 expression would be valuable for understanding how ecological variables might impact the tilapia endocrine system.

What techniques are most effective for detecting somatostatin-2 expression in tilapia tissues?

Based on the research methodologies described in the search results, several effective techniques for detecting somatostatin-2 expression include:

• RNA sequencing: Used to identify and quantify somatostatin variants in tilapia brain tissue, revealing the presence of three SST peptides (SST6, SST3, and low levels of SST1)

• In situ hybridization chain reaction (HCR): Applied to detect receptor expression in transgenic tilapia pituitaries (FSH:GFP and LH:RFP)

• Immunofluorescence assays: Used in conjunction with transgenic tilapia to visualize hormone-producing cells and their receptor expression

• Phylogenetic and synteny analysis: Employed to identify and classify somatostatin genes in the tilapia genome

For these approaches, tissue samples were processed with specific protocols:

• Fixation with 4% paraformaldehyde

• Immersion in PBS containing 20% sucrose and 30% OCT

• Sectioning at 12 μm on a cryostat

• Hybridization with specific probes designed for each tilapia SST receptor

How can recombinant somatostatin-2 be produced for experimental use?

While the search results don't directly describe production methods for recombinant somatostatin-2, standard recombinant protein production methodologies would apply:

• Gene cloning: The somatostatin-2 gene (designated as LOC100694069 in tilapia) would need to be amplified and cloned into an appropriate expression vector

• Expression systems:

  • Bacterial systems (E. coli) for high yield but potential challenges with disulfide bond formation

  • Yeast systems for better post-translational modifications

  • Mammalian cell systems for closest native folding and modifications

• Purification strategies:

  • Affinity chromatography using tagged constructs

  • Size exclusion chromatography

  • Reverse-phase HPLC for final purification

• Verification methods:

  • Mass spectrometry to confirm peptide identity

  • Circular dichroism to assess secondary structure

  • Receptor binding assays to confirm bioactivity

Each step would require optimization specific to somatostatin-2's characteristics, particularly regarding its small size and disulfide bond requirements.

What in vivo and in vitro models are appropriate for studying somatostatin-2 function in tilapia?

The search results describe several effective models for studying somatostatin-2 function:

• In vivo models:

  • Transgenic tilapia with fluorescent-labeled gonadotrophs (FSH:GFP and LH:RFP) for visualization of target cells

  • Direct injection of SSTR agonists (octreotide) and antagonists (cyclosomatostatin) to study effects on hormone release

  • Measurement of plasma hormone levels (LH, FSH) following treatment

• In vitro models:

  • Organ-cultured rostral pars distalis of tilapia for studying hormone release

  • FACS-sorted pituitary cell populations for cell-specific studies

  • cAMP activity assays to measure receptor response to agonists/antagonists

These models allow for complementary approaches: in vivo studies provide systemic context while in vitro approaches enable detailed mechanistic investigations under controlled conditions.

How can receptor binding assays be optimized for studying somatostatin-2 interactions with its receptors?

Based on the research methodologies, optimal receptor binding assays for somatostatin-2 should include:

• Receptor expression systems:

  • Using the identified tilapia SSTR isoforms (SSTR2a, SSTR3a, SSTR5b, and SSTR3b)

  • Expression in appropriate cell lines for functional studies

• Binding analysis approaches:

  • Comparative testing with known SSTR agonists (octreotide) and antagonists (cyclosomatostatin)

  • cAMP activity measurements to assess receptor activation

  • Calcium signaling assays, given the importance of Ca²⁺ in somatostatin's effects

• Structure-function analyses:

  • Using the generated 3D models of tiSSTRs and tiSSTs

  • Mutational analysis to identify key binding determinants

  • Docking studies to predict binding interactions

The research demonstrated that cyclosomatostatin induced cAMP activity in all SSTRs (with SSTR3a showing the highest response), while octreotide displayed a binding profile similar to human receptors . These findings provide a foundation for designing optimized receptor binding assays.

How might recombinant somatostatin-2 be applied in aquaculture research?

Recombinant somatostatin-2 has potential applications in tilapia aquaculture research:

• Reproductive control: Given somatostatin-2's role in regulating FSH and LH, it could potentially be used to modulate spawning timing or frequency in farmed tilapia

• Growth regulation: As somatostatin inhibits growth hormone release, manipulating this system could potentially optimize growth rates in aquaculture settings

• Stress response studies: Investigating how somatostatin-2 expression changes under different farming conditions could provide insights into stress physiology in tilapia

• Feed efficiency research: Understanding how somatostatin-2 influences metabolism could contribute to developing improved feeding strategies

The findings that octreotide decreased FSH levels while cyclosomatostatin increased both LH and FSH plasma levels suggest that selective manipulation of the somatostatin system could provide precise control over reproductive processes in aquaculture.

What are the most promising directions for future research on tilapia somatostatin-2?

Based on current knowledge gaps identified in the research, promising future directions include:

• Receptor-subtype specific functions: Further characterizing the distinct roles of different SSTR subtypes in mediating somatostatin-2 effects

• Integration with other hormonal systems: Investigating interactions between the somatostatin system and other key regulators like GnRH, dopamine, and growth hormone

• Environmental adaptation: Studying how environmental factors influence somatostatin-2 expression and function

• Comparative studies: Examining differences in somatostatin-2 function across tilapia species and other teleosts

• Therapeutic applications: Exploring potential uses of somatostatin analogs in managing reproductive or growth disorders in farmed fish

The researchers specifically noted that "further studies of the complex interplay between SST, its receptors, and reproductive hormones may advance reproductive control and management in cultured populations" , highlighting the importance of these research directions.

How does somatostatin-2 function compare between tilapia and other teleost species?

While the search results don't provide comprehensive comparative data, they do offer some insights:

• Somatostatin's inhibitory effect on gonadotropin-releasing hormone (GnRH) activity has been observed across multiple fish species including goldfish, common carp, and grass carp

• The development of SSTRs and their peptide ligands was influenced by various rounds of whole-genome duplication, with six paralogous genes of SSTR identified in vertebrates (SSTR1–6), five of which exist in medaka, stickleback, and takifugu

• Some SSTRs reported in trout and goldfish show ligand selectivity, while activation of SSTR2a in goldfish has been linked to inhibition of GH release

• Somatostatin's effects on pituitary hormone release have been studied in vivo and in vitro in several fish species, including salmon, goldfish, rainbow trout, and tilapia

These comparisons suggest both conservation and species-specific adaptations in somatostatin function across teleosts, with the tilapia system serving as an important model for understanding this regulatory network.

What are the common pitfalls in somatostatin receptor binding studies and how can they be avoided?

Based on the methodological approaches described in the research, several potential pitfalls and solutions can be identified:

• Receptor specificity challenges:

  • Pitfall: Cross-reactivity between different somatostatin receptor subtypes

  • Solution: Use receptor-specific antagonists and carefully designed binding competition assays

• Signaling pathway interpretation:

  • Pitfall: Overlooking the complexity of downstream signaling cascades

  • Solution: Employ multiple signaling readouts (cAMP, Ca²⁺, PKA) to comprehensively characterize receptor activation

• Binding conditions optimization:

  • Pitfall: Suboptimal conditions affecting binding kinetics

  • Solution: Systematically optimize temperature, pH, and buffer conditions for binding assays

• In vivo vs. in vitro discrepancies:

  • Pitfall: Differences between receptor behavior in isolated systems versus intact organisms

  • Solution: Validate findings across both in vitro receptor studies and in vivo physiological responses

The research demonstrated successful approaches by combining computational modeling, in vitro receptor assays, and in vivo hormone measurements to build a comprehensive picture of somatostatin-receptor interactions .

How can inconsistent results in somatostatin-2 expression studies be addressed?

When facing inconsistent results in somatostatin-2 expression studies, researchers should consider:

• Tissue preparation variability:

  • Standardize fixation protocols (e.g., 4% paraformaldehyde for 6h at 4°C as used in the research)

  • Use consistent sectioning techniques (12 μm sections on a cryostat at -18°C)

• Detection sensitivity issues:

  • Employ amplification techniques like hybridization chain reaction (HCR) to enhance signal

  • Use multiple detection methods (RNA-seq, in situ hybridization, immunofluorescence) for validation

• Physiological state variations:

  • Control for reproductive stage, stress levels, and feeding status

  • Document and account for environmental parameters (temperature, pH, dissolved oxygen)

• Technical variability in RNA-seq:

  • Ensure adequate sequencing depth (the research used at least 24M reads per library)

  • Apply appropriate bioinformatic pipelines (the research achieved >82% assignment to known genes)

The research successfully characterized the somatostatin system by employing multiple complementary approaches and carefully controlling experimental conditions .

What controls and validations are essential when working with recombinant somatostatin-2?

When working with recombinant somatostatin-2, essential controls and validations should include:

• Structural verification:

  • Mass spectrometry to confirm molecular weight and sequence

  • Circular dichroism to assess secondary structure

  • Comparison with native peptide if available

• Functional validation:

  • Receptor binding assays using known SSTR agonists (octreotide) and antagonists (cyclosomatostatin) as comparators

  • cAMP activity assays to confirm signaling capacity

  • Calcium mobilization studies to verify pathway activation

• Specificity controls:

  • Testing against multiple SSTR subtypes to establish binding preferences

  • Using receptor-null systems as negative controls

  • Comparing effects with known somatostatin variants (SST1, SST3, SST6)

• Physiological validation:

  • In vivo testing measuring hormone responses (FSH, LH, GH levels)

  • Dose-response studies to establish potency

  • Time-course experiments to determine pharmacokinetics

These controls would ensure that any recombinant somatostatin-2 being used experimentally faithfully represents the native peptide in both structure and function.

How should researchers interpret changes in somatostatin-2 expression across different physiological states?

When interpreting changes in somatostatin-2 expression across different physiological states, researchers should:

• Consider multiple regulatory inputs:

  • Evaluate whether expression changes are primary or secondary to other hormonal shifts

  • Analyze correlation with reproductive status, growth parameters, and stress indicators

• Employ appropriate statistical approaches:

  • Use methods that account for individual variability

  • Apply multiple testing corrections when examining expression across tissues or conditions

• Establish relevant baselines:

  • Define normal expression ranges for different developmental stages

  • Account for circadian or seasonal variations in expression

• Validate with functional outcomes:

  • Correlate expression changes with downstream effects on target hormones (FSH, LH, GH)

  • Confirm with receptor occupation and signaling activation measurements

The research demonstrated that somatostatin effects are context-dependent, with different impacts on FSH versus LH cells, highlighting the importance of cell-specific analysis rather than whole-tissue measurements .

What statistical approaches are most appropriate for analyzing receptor binding data for somatostatin-2?

Based on standard practices in receptor pharmacology and the approaches implied in the research, appropriate statistical approaches include:

• Dose-response analysis:

  • Nonlinear regression to determine EC50/IC50 values

  • Comparison of dose-response curves using F-tests or AIC criteria

• Binding kinetics:

  • Association and dissociation rate constant determination

  • Scatchard analysis or equivalent modern methods for affinity determination

• Comparative receptor analysis:

  • ANOVA with post-hoc tests to compare binding across receptor subtypes

  • Multiple regression to identify determinants of binding differences

• Time-course experiments:

  • Repeated measures ANOVA for analyzing temporal patterns

  • Area under the curve (AUC) analysis for cumulative effects

The research employed appropriate statistical approaches to identify significant differences in receptor enrichment between cell types and hormone responses to agonists/antagonists , providing a model for future studies.

How can genomic and transcriptomic data be integrated to better understand somatostatin-2 regulation?

The integration of genomic and transcriptomic approaches was demonstrated in the research, suggesting the following strategies:

• Comprehensive gene family characterization:

  • Phylogenetic analysis to identify all somatostatin variants and their evolutionary relationships

  • Synteny analysis to understand genomic context and evolutionary history

• Cell-type specific expression profiling:

  • FACS-sorting of specific cell populations (e.g., LH and FSH cells) followed by RNA-seq

  • Differential expression analysis to identify cell-specific enrichment of receptors

• Regulatory element identification:

  • Promoter analysis to identify transcription factor binding sites

  • Comparison of regulatory regions across species to identify conserved elements

• Integration with functional data:

  • Correlation of expression patterns with physiological responses

  • Identification of co-expressed genes for pathway analysis

The research successfully employed these approaches, revealing that SSTR3a was enriched in LH cells while SSTR3b was significantly enriched in FSH cells , providing insight into the cellular specificity of somatostatin action.

What are the most reliable databases and resources for tilapia somatostatin-2 research?

Based on the research methodologies described in the search results, reliable resources for tilapia somatostatin-2 research include:

• Genome databases:

  • ENSEMBL genome annotations (used for genomic and synteny analyses)

  • NCBI Gene Expression Omnibus (GEO) - the research data is available under accession number GSE169272

• Protein structure resources:

  • I-TASSER server (used for 3D modeling of tiSSTRs and tiSSTs)

  • PDB structures (human SSTR2-huSST-14, PDB:7T10 was used as template)

  • Schrödinger (BioLuminate) for structure processing and binding site prediction

• Phylogenetic analysis tools:

  • Maximum likelihood methods with JTT matrix-based model

  • Neighbor-Join and BioNJ algorithms for tree construction

• Gene identifiers specifically for tilapia somatostatin-2:

  • Gene Name: Somatostatin-2

  • Symbol: LOC100694069

  • Protein ID: XP_003448989.2

These resources provide the necessary tools and reference data for comprehensive analysis of the tilapia somatostatin system.

What experimental protocols have been validated for working with tilapia somatostatin-2?

The search results describe several validated experimental protocols:

• RNA sequencing of brain tissue:

  • Using Takara Bio Stranded Total RNA-seq Kit v2

  • Illumina NextSeq 500 system for sequencing

  • Analysis pipeline mapping to O. niloticus genome (assembly O._niloticus_UMD_NMBU GCA_001858045.3)

• In situ hybridization chain reaction:

  • Fixation with 4% paraformaldehyde for 6h at 4°C

  • Immersion in PBS with 20% sucrose and 30% OCT for 24h

  • 12 μm cryostat sections at -18°C

  • Incubation with denaturation probes at 37°C overnight

  • Specific washing and amplification steps

• Hormone measurement approaches:

  • Direct in vivo injection of SSTR agonists/antagonists

  • Plasma collection and hormone level determination

  • Organ culture of rostral pars distalis for in vitro studies

• Receptor binding and signaling assays:

  • cAMP activity measurements for receptor activation

  • Calcium signaling studies using ionophores and calcium exclusion

These protocols provide a comprehensive toolkit for investigating somatostatin-2 structure, expression, and function in tilapia.

What are the key reference standards and materials needed for somatostatin-2 research?

Based on the methodologies described in the search results, key reference standards and materials for somatostatin-2 research include:

• Pharmacological agents:

  • Cyclosomatostatin (SSTR antagonist)

  • Octreotide (SSTR agonist)

  • Calcium ionophore A23187

  • Dibutyryl cAMP (dbcAMP)

  • 3-isobutyl-1-methylxanthine (phosphodiesterase inhibitor)

• Genetic tools:

  • Transgenic tilapia lines (FSH:GFP and LH:RFP)

  • Specific probes for SST receptors (SSTR2a-B1, SSTR5b-B1, SSTR3a-B1, SSTR3b-B1)

• Analytical standards:

  • Reference sequences for tilapia somatostatin variants

  • Purified recombinant somatostatin peptides (if available)

• Control materials:

  • Wild-type tilapia of matched age/size

  • Appropriate vehicle controls for injections

  • Positive and negative control tissues for expression studies